An agreement on the United States–Mexico–Canada Agreement (USMCA), a trade deal that updates the North American Free Trade Agreement, has been reached, and proponents of biosimilars and generics have cause to celebrate after the removal of provisions that some said would hinder competition.
An agreement on the United States—Mexico–Canada Agreement (USMCA), a trade deal that updates the North American Free Trade Agreement, has been reached, and proponents of biosimilars and generics have cause to celebrate after the removal of provisions that some said would hinder competition.
The full text of the newly agreed version of the deal is yet to be publicly released. However, the chairman of the House Committee on Ways and Means, Richard Neal, D-Massachusetts, said in a statement outlining features of the final agreement that House Democrats were successful in their attempts to remove provisions of the deal that would have required all parties to provide at least 10 years of exclusivity for biologic drugs, to remove provisions that would have allowed patent evergreening on drugs, and to cut provisions that would allow 3 extra years of exclusivity for clinical information submitted in connection with new uses of existing products.
The revised agreement also includes clarification on circumstances in which generic and biosimilar developers can use patented inventions in order to gain marketing approval on the first day after patent expiry.
Biosimilars and generics trade group the Association for Accessible Medicines called the revised deal a victory for patients, saying that the new agreement creates greater opportunities for patients in all 3 nations to access less expensive prescription drugs.
The Canadian Generic Pharmaceutical Association also praised the deal; president Jim Keon said that the removal of the 10-year exclusivity provision is particularly important for Canadian patients, noting that the provision could have delayed the availability of biosimilar medicines in Canada, where biosimilars are increasingly seen as a crucial part of national attempts to reduce prescription drug costs.
In the United States, AARP’s executive vice president and chief advocacy and engagement officer, Nancy LeaMond, said in a statement that “there is no reason why the [United States] should continue to pay the highest drug prices in the world. Americans, along with our Canadian and Mexican neighbors, scored a noteworthy victory today against ‘big pharma’ that pushed hard to keep these provisions in the USMCA.”
Perhaps unsurprisingly, the Pharmaceutical Research and Manufacturers of America, or PhRMA, which represents innovator drug makers, took a dim view of the revisions; president and chief executive officer Stephen J. Ubl said that removal of biologics exclusivity provisions would do “nothing” to help patients, and that the revised deal will help foreign governments “who want to steal American intellectual property and free ride on America’s global leadership."
Similarly, the Biotechnology Innovation Organization, which represents biotech companies, said that the United States had given up an important tool to “end foreign free-riding on American medical innovation.”
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.